Article
Deletion Mutations Keep Kinase Inhibitors in the Loop.
Cancer cell - 11 Apr 2016
Freed Daniel M, Park Jin H, Radhakrishnan Ravi, Lemmon Mark A
Abstract excerpt
Effective clinical application of conformationally selective kinase inhibitors requires tailoring drug choice to the tumor's activating mutation(s). In this issue of Cancer Cell, Foster et al. (2016) describe how activating deletions in BRAF, EGFR, and HER2 cause primary resistance to common inhibitors, suggesting strategies for improved inhibitor selection.
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.